Sun‑Novo, Byterna, and CAR‑T/CircRNA Collaboration Propel In‑Vivo Gene‑Therapy Frontiers
Beijing Sun‑Novo Pharmaceutical Research Co., Ltd. today disclosed a strategic capital injection of RMB 15 million into...
Sun-Novo Pharmaceutical Research
Lexenpharm Partners with AptarGroup for Single-Dose Nasal Spray Services in Greater China
China-based Lexenpharm late last week announced a strategic partnership with Aptar Pharma, a US-based global...
Sun-Novo Pharma Collaborates with LeKuang Huilin on STC007 for Post-Abdominal Surgery Pain
China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) this week entered into a technology...
Sun-Novo Partners with Youjia Biomedical to Develop Antibody-Oligonucleotide Conjugate for Metabolic Diseases
China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has formed a partnership with compatriot...
Anlong Biopharmaceutical and Sun-Novo Partner to Advance siRNA Technology in Cardiovascular Treatments
On March 10, 2025, Anlong Biopharmaceutical and Sun-Novo Pharmaceutical announced a strategic partnership to advance...
Lexenpharm and Sun-Novo Partner on Long-Acting Asthma and COPD Drugs
China-based Lexenpharm has formed a partnership with compatriot firm Beijing Sun-Novo Pharmaceutical Research Co., Ltd...
Sun-Novo Pharmaceuticals Gets Green Light for CAR-T Therapy Clinical Trial in Lupus Treatment
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) has secured approval from China’s National Medical...
Beijing Sun-Novo Gets NMPA Green Light for STC008 Clinical Trial in Tumor Cachexia
Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621), a biopharmaceutical company based in China, has...
Beijing Sun-Novo and Zhejiang Anglikang Deepen Ties with New Drug Development Partnership
Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621), a pharmaceutical company based in China, has...
Beijing Sun-Novo and Zhejiang Anglikang Enter Licensing Agreement for Hypertension Drug Candidate NHKC-1
Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced a significant licensing agreement with...
Beijing Sun-Novo Secures Exclusive Rights to Kaneka’s Skin Patch Drugs in Licensing Deal
China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced a licensing agreement with...
Sun-Novo Pharma to Acquire MAH Rights for Azilsartan from Baiao Pharma
China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced plans to acquire the...
Sun-Novo Pharma Gains NMPA Approval for STC007 Clinical Study in CKD-aP
China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced receiving approval from the...
Sun-Novo’s STC007 Gains NMPA Approval for Postoperative Pain Study
China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd has announced that it has received approval from...